News
Overcoming Limitations of Kinase Inhibitors in Cancer Therapy
Table of contents
Work with us
Whether you’re a researcher, investor, or biotech leader, let’s explore how we can make a real impact together.
Contact us
Share this article
May 14, 2025

Challenges with Traditional Kinase Inhibitors

Traditional kinase inhibitors have shown promise in cancer therapy; however, they often face limitations such as short-lived efficacy and adverse effects. These challenges necessitate the development of new therapeutic strategies.

Addressing Short-Lived Efficacy

Many kinase inhibitors provide only temporary responses, leading to disease progression. New approaches, including combination therapies and novel inhibitors, aim to extend the duration of response and improve patient outcomes.

Innovative strategies are essential for overcoming these limitations.

Reducing Adverse Effects

Adverse effects can significantly impact patient quality of life. By developing more selective inhibitors, researchers aim to minimize side effects while maintaining therapeutic efficacy, ultimately enhancing the overall treatment experience.

Work with us
Whether you’re a researcher, investor, or biotech leader, let’s explore how we can make a real impact together.
Contact us
Share this article